AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7514356
Drug: Continuous IV
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous IV infusion of ketorolac
Trial: 31748208
Drug: Platelet rich
RxNorm normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet rich plasma injection
Trial: 31748208
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection (dry needle)
Trial: 28894836
Drug: Tinnitus Retraining
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinnitus Retraining Therapy (TRT) consisting of directive counseling and acoustic enrichment using combination hearing aids and sound generators
Trial: 28894836
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care treatment (SC) consisting of general aural rehabilitation counseling and hearing aids
Trial: 22930403
Drug: Curcuminoids (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuminoids (300 mg/day)
Trial: 21810242
Drug: Training and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training and guidelines for nurse ART prescription, local management teams, and implementation toolkit.
Trial: 8466742
Drug: Isradipine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (2.5 mg once daily)
Trial: 8466742
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg once daily) added to nitrendipine
Trial: 8466742
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg once daily) added to isradipine
Trial: 27274349
Drug: Cotton-roll vibration
RxNorm normalized name: Cotton
DrugBank: Cotton (DB10707)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotton-roll vibration method (a combination of topical anesthesia gel, cotton roll, and vibration for physical distraction)
Trial: 27274349
Drug: Routine topical
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine topical anesthesia (control)
Trial: 18445178
Drug: Captopril (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (100 mg) with low-dose bendroflumethiazide (1.25 mg)
Trial: 8251413
Drug: Schedule M
RxNorm normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule M (intermediate dose methotrexate with folinic acid rescue)
Trial: 3895828
Drug: Routine duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine duration of oral anticoagulation (standard duration)
Trial: 3895828
Drug: 50% reduction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% reduction in duration of oral anticoagulation (reduced duration)
Trial: 30167675
Drug: Dextroamphetamine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine (10 mg) combined with physical therapy
Trial: 30167675
Drug: Placebo combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo combined with physical therapy
Trial: 27861718
Drug: Cognitively stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitively stimulating activities (daily for up to 30 days)
Trial: 27781421
Drug: Fosdagrocorat 5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosdagrocorat 5, 10, or 30 mg (single doses)
Trial: 27781421
Drug: Fosdagrocorat 20
RxNorm normalized name: Fosdagrocorat
DrugBank: Fosdagrocorat (DB12198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosdagrocorat 20 mg QD (multiple doses for 12 days)
Trial: 1854464
Drug: Placebo (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (single and multiple doses)
Trial: 16172794
Drug: Toremifene 60
RxNorm normalized name: toremifene 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene 60 mg/day
Trial: 10587476
Drug: (R)-salbutamol 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (R)-salbutamol 1.25 mg
Trial: 10587476
Drug: (RS)-salbutamol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (RS)-salbutamol 2.5 mg
Trial: 1751787
Drug: Immunoglobulin G
RxNorm normalized name: immunoglobulin G
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoglobulin G (400 mg/kg body wt)
Trial: 1751787
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline; 8 mL/kg body wt)
Trial: 1751787
Drug: Immunoglobulin G
RxNorm normalized name: immunoglobulin G
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoglobulin G
Trial: 7076630
Drug: Fluphenazine decanoate
RxNorm normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluphenazine decanoate (continued treatment)
Trial: 31030872
Drug: Infant Behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infant Behavior Program (a brief, home‐based adaptation of the child‐directed interaction phase of parent‐child interaction therapy)
Trial: 28273891
Drug: Magnesium supplementation
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium supplementation (350 mg daily for 24 weeks)
Trial: 10491058
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of strontium salts
Trial: 2140743
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg b.i.d.)
Trial: 31287117
Drug: Montmorency tart
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montmorency tart cherry juice (2 cups daily for 12 weeks)
Trial: 10686535
Drug: Cladribine (exact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cladribine (exact dosage and duration not available)
Trial: 10686535
Drug: Interferons (exact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferons (exact dosage and duration not available)
Trial: 9296731
Drug: Multivitamin consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin consumption including 0.8 mg folic acid
Trial: 1592976
Drug: Dentifrice formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dentifrice formulations containing NaF, xylitol, or NaF/xylitol
Trial: 30275698
Drug: Eplerenone 100
RxNorm normalized name: eplerenone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone 100 mg daily
Trial: 24643639
Drug: JET combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JET combination therapy
Trial: 15702515
Drug: Rizatriptan nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rizatriptan nasal spray (5 mg)
Trial: 15702515
Drug: Oral rizatriptan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rizatriptan tablet (5 mg)
Trial: 12848628
Drug: Prednisolone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (30 mg/day for 3 weeks)
Trial: 10700887
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy for locally unresectable cancer in the oral cavity, pharynx, and nose and paranasal sinus
Trial: 10700887
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy plus adjuvant chemotherapy for advanced N stage nasopharyngeal cancer
Trial: 10700887
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy for advanced T stage nasopharyngeal cancer
Trial: 10700887
Drug: Neoadjuvant and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant and/or concurrent chemoradiotherapy for T2 and T3 laryngeal and hypopharyngeal cancer
Trial: 9038610
Drug: recombinant interleukin-2
RxNorm normalized name: Recombinant interleukin-2 human
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: recombinant interleukin-2 (rIL-2) with chemotherapy (5-fluorouracil and leucovorin)
Trial: 1665285
Drug: Zileuton (A-64077)
RxNorm normalized name: Zileuton
DrugBank: Zileuton (DB00744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zileuton (A-64077) 600 mg q.i.d. for 14 days
Trial: 16649820
Drug: Quetiapine (pooled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (pooled doses)
Trial: 12414914
Drug: weight-adjusted heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: weight-adjusted heparin
Trial: 12414914
Drug: oral compounds
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral compounds
Trial: 10400458
Drug: Antioxidant infusion
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant infusion containing tocopherol and ascorbate
Trial: 10400458
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no antioxidant infusion)
Trial: 8524969
Drug: brotizolam 0.25
RxNorm normalized name: brotizolam 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brotizolam 0.25 mg
Trial: 23982942
Drug: Telephone survey
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone survey administration (n = 99)
Trial: 23072847
Drug: Yoyo Bitters
RxNorm normalized name: BITTER MELON
DrugBank: Momordica charantia fruit (DB14265)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoyo Bitters (1206.5 mg/kg)
Trial: 23072847
Drug: Yoyo Bitters
RxNorm normalized name: BITTER MELON
DrugBank: Momordica charantia fruit (DB14265)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoyo Bitters (804.3 mg/kg)
Trial: 12407324
Drug: Conventional hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional hormone replacement therapy (HRT)
Trial: 2258349
Drug: Pefloxacin (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pefloxacin (oral treatment for a mean duration of 13 days)
Trial: 2258349
Drug: Ceftazidime (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (intravenous treatment for a mean duration of 10 days)
Trial: 30674315
Drug: Maternal pre-pregnancy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal pre-pregnancy BMI and weekly gestational weight gain
Trial: 30674315
Drug: Weekly gestational
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly gestational weight gain
Trial: 22819555
Drug: lycopene-rich diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lycopene-rich diet (224-350 mg lycopene/week)
Trial: 22819555
Drug: lycopene supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lycopene supplement (70 mg lycopene/week)
Trial: 22819555
Drug: control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control diet (<10 mg lycopene/week)
Trial: 14628939
Drug: Sulfadoxine-pyrimethamine (SP)
RxNorm normalized name: pyrimethamine / sulfadoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine-pyrimethamine (SP) treatment
Trial: 2938886
Drug: Combined pill
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined pill (oral contraceptive)
Trial: 2938886
Drug: Progestin-only pill
RxNorm normalized name: Prostin E2 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progestin-only pill
Trial: 2938886
Drug: DMPA and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMPA and progestin-only treatment
Trial: 30032176
Drug: Polyphenol-rich extract
RxNorm normalized name: Pomegranate Fruit Polyphenol Extract
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyphenol-rich extract from grape and blueberry (PEGB) 600 mg/day for 6 months
Trial: 27264945
Drug: Clonidine 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 3 µg per kg
Trial: 22226008
Drug: Treatment combinations
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment combinations including insulin
Trial: 22226008
Drug: Treatment combinations
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment combinations including thiazolidinediones
Trial: 22226008
Drug: Treatment combinations
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment combinations including sulphonylureas
Trial: 20855825
Drug: Fulvestrant 500
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant 500 mg and Fulvestrant 250 mg
Trial: 15844709
Drug: INF alfacon‐1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INF alfacon‐1, 15 microg three times per week, plus ribavirin, 1 g/day
Trial: 15844709
Drug: IFN‐alpha2b, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN‐alpha2b, 3 million units three times per week, plus ribavirin, 1 g/day
Trial: 8659037
Drug: Radiation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation treatment (group 1)
Trial: 8659037
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and estrogens in addition to radiation (group 2)
Trial: 8659037
Drug: Drugs and
RxNorm normalized name: Prostaglandin analogues, antiglaucoma drugs and miotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs and estrogens (group 3)
Trial: 1467075
Drug: Extradural bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extradural bupivacaine 10 ml
Trial: 1467075
Drug: Extradural saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extradural saline 10 ml
Trial: 1467075
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no extradural injection)
Trial: 6329021
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg orally every 6 hours
Trial: 6329021
Drug: Conventional alkali
RxNorm normalized name: alkali blite pollen extract
DrugBank: Suaeda moquinii pollen (DB10953)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional alkali therapy
Trial: 28874133
Drug: Sildenafil (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (20 mg, 3 times daily)
Trial: 26905220
Drug: BNP-guided heart
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNP-guided heart failure treatment
Trial: 21715446
Drug: BNP-guided heart
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNP-guided heart failure treatment (responders)
Trial: 21715446
Drug: BNP-guided heart
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNP-guided heart failure treatment (non-responders)
Trial: 8444538
Drug: Topical phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical phenytoin
Trial: 2804250
Drug: Methylprednisolone phosphate
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone phosphate (doses between 16 and 1000 mg)
Trial: 31308191
Drug: MDMA-assisted psychotherapy
RxNorm normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA-assisted psychotherapy (8-week course, including two therapy sessions with MDMA)
Trial: 25861737
Drug: BI 671800
RxNorm normalized name: BI-671800
DrugBank: BI-671800 (DB12524)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 671800 50 mg bid
Trial: 25861737
Drug: BI 671800
RxNorm normalized name: BI-671800
DrugBank: BI-671800 (DB12524)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 671800 200 mg bid
Trial: 25861737
Drug: BI 671800
RxNorm normalized name: BI-671800
DrugBank: BI-671800 (DB12524)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 671800 400 mg bid
Trial: 25861737
Drug: Fluticasone 220
RxNorm normalized name: fluticasone 220 mcg/inh inhalation aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone 220 μg bid
Trial: 25861737
Drug: Montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg qd
Trial: 23471101
Drug: Niccine 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niccine 40 μg
Trial: 21660523
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of tranexamic acid (2.5 g in 250 ml normal saline)
Trial: 11280365
Drug: Bone grafting
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone grafting and implant placement (graft group)
Trial: 11280365
Drug: Modified implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified implant placement with no bone grafting (trial group)
Trial: 11280365
Drug: Optimized complete
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized complete dentures (no‐implant group)
Trial: 9594320
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose urokinase (22,000 IU/kg, total dose not lower than 1.2 million IU)
Trial: 9594320
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose urokinase (30,000 IU/kg, total dose not more than 2.4 million IU)
Trial: 1900094
Drug: Danazol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (200 mg/day)
Trial: 27480103
Drug: Cobimetinib (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cobimetinib (60 mg once daily for 21 days followed by a 7-day rest period in each 28-day cycle) plus vemurafenib (960 mg twice daily)
Trial: 27480103
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus vemurafenib (960 mg twice daily)
Trial: 24740547
Drug: HPV vaccine
RxNorm normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV vaccine (specific dosage and duration not mentioned)
Trial: 20093351
Drug: ECisF (epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECisF (epirubicin 60 mg/m², cisplatin 60 mg/m², 5-FU 200 mg/m² by daily 24-h infusion)
Trial: 20093351
Drug: FEC (5-FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEC (5-FU 600 mg/m², epirubicin 60 mg/m², cyclophosphamide 600 mg/m²)
Trial: 18505852
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg TMC207
Trial: 18505852
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg TMC207
Trial: 18505852
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg TMC207
Trial: 9310010
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg isoniazid (INH)
Trial: 18505852
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg rifampin (RIF)
Trial: 15920220
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg orally the evening before surgery and 4 mg IV 15 min before subarachnoid anesthesia
Trial: 8115316
Drug: Nitrendipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (20 mg daily for 1 month)
Trial: 2960694
Drug: Thromboxane receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thromboxane receptor antagonist BM 13.177 and thromboxane synthase inhibitor dazoxiben
Trial: 21118410
Drug: Dual non‐parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual non‐parenteral combination therapy (including bosentan, sitaxentan, ambrisentan, iloprost, and sildenafil)
Trial: 21118410
Drug: Dual non‐parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual non‐parenteral combination therapy
Trial: 19693799
Drug: Paliperidone ER
RxNorm normalized name: Paliperidone ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paliperidone ER 6 mg alone
Trial: 19693799
Drug: Trimethoprim 200
RxNorm normalized name: trimethoprim 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim 200 mg twice daily
Trial: 9755355
Drug: Serotonergic antidepressants
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonergic antidepressants (e.g., selective serotonin reuptake inhibitors)
Trial: 9755355
Drug: Noradrenergic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noradrenergic and mixed serotonergic/noradrenergic tricyclic antidepressants
Trial: 20631574
Drug: Low-dose naltrexone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose naltrexone
Trial: 19551680
Drug: Macular laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macular laser photocoagulation (MP) after intravitreal injection of 4 mg of triamcinolone acetonide (IVTA)
Trial: 19551680
Drug: Macular laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macular laser photocoagulation (MP) concomitant with intravitreal injection of 4 mg of triamcinolone acetonide (IVTA)
Trial: 19551680
Drug: Only intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only intravitreal injection of 4 mg of triamcinolone acetonide (IVTA)
Trial: 2156476
Drug: Ganciclovir, 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganciclovir, 2.5 mg/kg body weight every 8 hours for 14 days
Trial: 396054
Drug: 3 x
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 20 mg/kg praziquantel